Ciprofloxacin and ofloxacin are broad-spectrum antibiotics with activity against Gram-positive and especially Gram-negative organisms. They are also active against some anaerobes and Chlamydia and Mycoplasma species. Since their launch, quinolones have been widely used, and this has led to the emergence of resistance in some bacterial species. This has been seen in the GUM setting, where in some geographical areas in the UK the increasing amount of gonorrhoea resistant to ciprofloxacin has led to its no longer being considered as a first-line empirical treatment in local guidelines for this condition.
Was this article helpful?